Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe Acute Proximal Pulmonary Embolism and COVID-19: A Word of Caution

Olivier Fabre, MD, PhD, Olivier Rebet, MD, Ionut Carjaliu, MD, Mihai Radutoiu, MD, Laurence Gautier, MD, and Ilir Hysi, MD

Department of Cardiac Surgery of Artois, Hospital Center of Lens, Lens, France; and Private Hospital of Bois-Bernard, Ramsay Santé, France

Acute pulmonary embolism is an uncharacteristic presentation in patients with coronavirus 2019 (COVID-19). Here we describe the case of a young woman presenting with severe pulmonary embolism, without any associated symptoms of infections. A clot in a patent foramen ovale was noted. Despite emergency surgical embolectomy, her clinical conditions continued to deteriorate. She was put on extracorporeal life support and tested positive for COVID-19. She died of multiorgan failure on day 10. COVID-19 may have a thrombogenic effect, and it may need to be considered in cases of pulmonary embolism and in the absence of any obvious risk factor.

© 2020 by The Society of Thoracic Surgeons

Arterial blood gas measurements revealed $P_{O_2}$ 54 mm Hg and $P_{CO_2}$ 21 mm Hg. Her C-reactive protein level was 20 mg/L, and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) was 11,021 pg/mL. Bedside transthoracic echocardiography showed left ventricular ejection fraction of 65% and a hypokinetic right ventricle (tricuspid annular plane systolic excursion 13 mm, $S$ wave 8 cm/s) associated with severe systolic pulmonary hypertension (95 mm Hg). A patent foramen ovale was present with a large thrombus originating from the right atrium and extending to the left atrium. Contrast-enhanced CT scan showed massive bilateral proximal pulmonary embolism (Figure 1A, 1B). Because of the elevated risk of systemic embolism, thrombolysis was not considered.

The patient was transferred immediately to the operating room, and as per our routine practice in our center for these unstable patients, cardiopulmonary bypass was established under local anesthesia, by surgical cutdown of the femoral vessels at the level of the right groin. Surgical embolectomy was performed through median sternotomy after arresting the heart (Figure 1C, 1D). The patient’s clinical condition stabilized during her first week in the intensive care unit. However, she had some degree of right heart failure, and despite administration of fluid resuscitation and vasopressors, she had persistent vasoplegic syndrome. Also, weaning from the ventilator was not possible. A Doppler peripheral echography revealed a deep venous thrombosis at the level of the left leg without any floating clot inside the inferior vena cava.

On day 8, she had severe hypoxemia refractory to maximum mechanical ventilation. She was put in a prone position for 16 hours, which improved gas blood oxygenation. On day 9, while remaining in the supine position, the patient had fever (42°C), hypoxemia ($P_{O_2}$ 54 mm Hg), and severe septic shock. Computed tomography scan was not done owing to her unstable clinical condition, but chest roentgenogram showed extensive bilateral interstitial infiltration (Figure 2). Transthoracic echocardiography was stable and showed no further impairment of right or left ventricular function. The patient was tested for COVID-19 at that time, and put on venous arterial extracorporeal life support as a rescue treatment (flow 6.4 L/min). Polymerase chain reaction test for COVID-19 was positive. The patient’s clinical condition deteriorated rapidly, and she died of multiorgan failure on March 28, 2020, day 10 after embolectomy.

A post hoc analysis of the initial CT scan, made by the radiologists, found there were already slight bilateral interstitial ground-glass opacities compatible with COVID-19 lung parenchymal lesions (Figure 3).

Comment

COVID-19 related pathology has been constantly evolving during the past month. The association between acute pulmonary embolism and COVID-19 has been reported only in two very recent publications. Unlike our
patient whose clinical presentation was dominated by acute embolism, with no fever, cough, and muscular fatigue, in those publications pulmonary embolisms were diagnosed retrospectively on the CT scans of patients having COVID-19 “classic” infectious respiratory clinical presentation. Our patient was not identified as a potential COVID-19 patient and was not tested because her strong chest pain, syncope, and tachypnea were attributed to the acute proximal pulmonary embolism, and except for the dyspnea and sore throat, she did not have the symptoms usually associated with COVID-19.

The probability of a nosocomial COVID-19 infection during our patient’s hospital stay is minimal as she remained intubated in sterile conditions in the intensive care unit with no member of the attending team testing positive or having any COVID-19 signs over this period. Moreover, a post hoc analysis indicated the initial CT scan already showed signs consistent with COVID-19 lung lesions.

It is difficult to take a definite position on the role of treatment our patient received before her admission to the hospital. Angiotensin-converting enzyme 2 is a co-receptor for viral entry for SARS-CoV-2, and it may have a role in COVID-19 pathogenesis, although there is insufficient evidence to link angiotensin-converting enzyme inhibitors or renin-angiotensin system blockers to severe forms of COVID-19. A similar uncertainty exists as to the role of the patient’s ibuprofen oral intake and its potential relationship with severe forms of COVID-19.

Although the evidence is insufficient to establish a firm association between pulmonary embolism and COVID-19, the latter may have a thrombogenic effect and eventually cause pulmonary embolism. Cases of pulmonary embolism were also noted during the coronavirus severe acute respiratory syndrome epidemic in 2003. Indeed, an underlying thrombophilic state, with frequent pulmonary embolisms in necropsy series of severe acute respiratory syndrome patients, was reported.

In conclusion, we want to raise awareness that potentially COVID-19 and severe acute pulmonary embolism may be related, and in the absence of clear symptoms currently associated with this viral infection, the clinic may be totally dominated by the hemodynamic or respiratory symptoms of acute pulmonary embolism. For this reason, when presented with a patient with pulmonary embolism, without any evident risk factor for this pathology, the potential association between COVID-19 and pulmonary embolism should also be considered. If true, the early
detection of COVID-19 infection can lead to prompter and more aggressive systemic treatment, according to local recommendations or evaluation protocols.

References
1. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382:2012-2022.
2. Zhang C, Huang S, Zheng F, Dai Y. Controversial treatments: an updated understanding of the coronavirus disease 2019. J Med Virol. 2020;92:1441-1448.
3. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41:1858.
4. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology. 2020;2:e200067.
5. Danser AHJ, Epstein M, Battle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382-1385.
6. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653-1659.
7. Day M. COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086.
8. Ng KHL, Wu AKL, Cheng VCC, et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J. 2005;81:x3.